217 related articles for article (PubMed ID: 29048402)
1. miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis.
Yang RM; Zhan M; Xu SW; Long MM; Yang LH; Chen W; Huang S; Liu Q; Zhou J; Zhu J; Wang J
Cell Death Dis; 2017 Oct; 8(10):e3129. PubMed ID: 29048402
[TBL] [Abstract][Full Text] [Related]
2. Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis.
Yu S; Wang M; Zhang H; Guo X; Qin R
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828307
[TBL] [Abstract][Full Text] [Related]
3. miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer.
Liu F; Liu B; Qian J; Wu G; Li J; Ma Z
Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):520-529. PubMed ID: 28459992
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
Ma J; Fang B; Zeng F; Ma C; Pang H; Cheng L; Shi Y; Wang H; Yin B; Xia J; Wang Z
Oncotarget; 2015 Jan; 6(3):1740-9. PubMed ID: 25638153
[TBL] [Abstract][Full Text] [Related]
5. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
[TBL] [Abstract][Full Text] [Related]
6. miR-1271 inhibits migration, invasion and epithelial-mesenchymal transition by targeting ZEB1 and TWIST1 in pancreatic cancer cells.
Liu H; Wang H; Liu X; Yu T
Biochem Biophys Res Commun; 2016 Apr; 472(2):346-52. PubMed ID: 26940738
[TBL] [Abstract][Full Text] [Related]
7. miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer.
Hiramoto H; Muramatsu T; Ichikawa D; Tanimoto K; Yasukawa S; Otsuji E; Inazawa J
Sci Rep; 2017 Jun; 7(1):4002. PubMed ID: 28638102
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of MBD1 promotes pancreatic cancer cell epithelial-mesenchymal transition and invasion by epigenetic down-regulation of E-cadherin.
Xu J; Zhu W; Xu W; Yao W; Zhang B; Xu Y; Ji S; Liu C; Long J; Ni Q; Yu X
Curr Mol Med; 2013 Mar; 13(3):387-400. PubMed ID: 23331011
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
Li Y; VandenBoom TG; Kong D; Wang Z; Ali S; Philip PA; Sarkar FH
Cancer Res; 2009 Aug; 69(16):6704-12. PubMed ID: 19654291
[TBL] [Abstract][Full Text] [Related]
10. MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20.
Yao J; Li Z; Wang X; Xu P; Zhao L; Qian J
Acta Biochim Biophys Sin (Shanghai); 2016 Feb; 48(2):202-8. PubMed ID: 26758190
[TBL] [Abstract][Full Text] [Related]
11. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells.
Funamizu N; Lacy CR; Kamada M; Yanaga K; Manome Y
Int J Oncol; 2019 Mar; 54(3):991-1000. PubMed ID: 30628651
[TBL] [Abstract][Full Text] [Related]
13. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
14. MiR-539 functions as a tumor suppressor in pancreatic cancer by targeting TWIST1.
Yu H; Gao G; Cai J; Song H; Ma Z; Jin X; Ji W; Pan B
Exp Mol Pathol; 2019 Jun; 108():143-149. PubMed ID: 31022384
[TBL] [Abstract][Full Text] [Related]
15. MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer.
Wu ZH; Tao ZH; Zhang J; Li T; Ni C; Xie J; Zhang JF; Hu XC
Tumour Biol; 2016 Jun; 37(6):7245-54. PubMed ID: 26666820
[TBL] [Abstract][Full Text] [Related]
16. LncRNA CHRF-induced miR-489 loss promotes metastasis of colorectal cancer via TWIST1/EMT signaling pathway.
Tao Y; Han T; Zhang T; Ma C; Sun C
Oncotarget; 2017 May; 8(22):36410-36422. PubMed ID: 28430582
[TBL] [Abstract][Full Text] [Related]
17. Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer.
Gu J; Huang W; Wang X; Zhang J; Tao T; Zheng Y; Liu S; Yang J; Chen ZS; Cai CY; Li J; Wang H; Fan Y
Mol Cancer; 2022 May; 21(1):112. PubMed ID: 35538494
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of miR-210 involved in epithelial-mesenchymal transition of pancreatic cancer cells under hypoxia.
Ni J; Zhou S; Yuan W; Cen F; Yan Q
J Recept Signal Transduct Res; 2019; 39(5-6):399-406. PubMed ID: 31875764
[No Abstract] [Full Text] [Related]
19. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.
Lu H; Lu S; Yang D; Zhang L; Ye J; Li M; Hu W
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30777929
[TBL] [Abstract][Full Text] [Related]
20. The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells.
Wang R; Li Y; Hou Y; Yang Q; Chen S; Wang X; Wang Z; Yang Y; Chen C; Wang Z; Wu Q
Oncotarget; 2015 Mar; 6(9):7000-10. PubMed ID: 25760076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]